Loading organizations...
§ Venture Capital
an investment and holding entity facilitating investments in real estate, venture capital, and private equity.
Dieckell Group, operating via Milan Capital, specializes in commercial real estate acquisition, development, and management. The firm identifies and secures multi-family and commercial properties, overseeing their full lifecycle. Core capabilities include strategic planning, financial oversight, and securing entitlements, all designed to optimize portfolio performance and asset value.
Claus Dieckell, a seasoned entrepreneur with a retail and technology background, founded the enterprise. He established its real estate foundation by re-entering the Southern California market in 1993, after an earlier multi-family portfolio divestment. His return was strategically timed to capitalize on significant market value declines, a core insight guiding the firm's investment approach.
The firm primarily serves investors seeking value and growth in commercial real estate, managing an extensive property portfolio. Dieckell Group's vision centers on disciplined expansion and maximizing returns. It continually refines strategies to enhance efficiency and capacity, aiming to cultivate a resilient and growing real estate presence.
Dieckell Group has 2 tracked investments across 1 company. The latest tracked deal is $2.8M Series D Extension in TME Pharma in October 2010.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 12, 2010 | TME Pharma | $2.8M Series D Extension | — | Sofinnova Partners, CD Venture, Dewb, IBB Ventures, IBG Sachsen Anhalt, NGN Capital, Oppenheim Asset Management Services, Seventure Partners, The DOW Chemical Company, TVM Capital |
| May 1, 2010 | TME Pharma | $41.0M Series D | NGN Capital | Andera Partners, FCP OP MEDICAL BioHealth Trends, IBB Ventures, IBG Sachsen Anhalt, Seventure Partners, Sofinnova Partners, The DOW Chemical Company, TVM Capital |